Bronchial Rheoplasty For Treatment of Chronic Bronchitis: 12 Month Results from a Multi-Center Study.

MedStar author(s):
Citation: American Journal of Respiratory & Critical Care Medicine. 202(5):681-689, 2020 09 01.PMID: 32407638Institution: MedStar Franklin Square Medical CenterDepartment: Angelos Center for Lung DiseaseForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Ablation Techniques/mt [Methods] | *Bronchi/su [Surgery] | *Bronchitis, Chronic/su [Surgery] | Aged | Bronchitis, Chronic/pp [Physiopathology] | Disease Progression | Female | Follow-Up Studies | Forced Expiratory Volume | Humans | Male | Prospective Studies | Quality of Life | Time Factors | Treatment OutcomeYear: 2020Local holdings: Available online from MWHC library: July 1997 - present, Available in print through MWHC library: 1999 - presentISSN:
  • 1073-449X
Name of journal: American journal of respiratory and critical care medicineAbstract: CONCLUSIONS: This study provides the first clinical evidence of the feasibility, safety and initial outcomes of Bronchial Rheoplasty in symptomatic chronic bronchitis patients.MEASUREMENTS AND MAIN RESULTS: Bronchial Rheoplasty was performed in all 30 patients [63% male, mean age 67 (standard deviation 7.4), post-bronchodilator Forced Expiratory Volume in 1 second 65% (21%), COPD Assessment Test score 25.6 (7.1), and St. George's Respiratory Questionnaire score 59.6 (15.3)]. There were no device-related and 4 procedure-related serious adverse events through 6 months, and none thereafter through 12 months. The most frequent non-serious, device and/or procedure related event through 6 months was mild hemoptysis in 47% (14/30) patients. Histologically, mean goblet cell hyperplasia score was statistically significantly reduced (p<0.001). Significant changes from baseline to 6 months in COPD Assessment Test (mean -7.9; median -8.0; p=0.0002) and St. George's Respiratory Questionnaire (mean -14.6; median -7.2; p=0.0002) were observed, with similar observations through 12 months.METHODS: Pooled analysis of two separate studies enrolling 30 patients undergoing bilateral Bronchial Rheoplasty. Follow-up through 6 months (primary outcome) and 12 months included assessment of adverse events, airway histology and changes in symptoms using the COPD Assessment Test and St. George's Respiratory Questionnaire.OBJECTIVES: To evaluate the feasibility, safety and initial outcomes of Bronchial Rheoplasty in chronic bronchitis patients.RATIONALE: Chronic bronchitis is characterized by productive cough with excessive mucus production, resulting in quality of life impairment and increased exacerbation risk. Bronchial Rheoplasty uses an endobronchial catheter to apply non-thermal pulsed electric fields to the airways. Preclinical studies demonstrated epithelial ablation followed by regeneration of normalized epithelium.All authors: Dabscheck EJ, Fernandez-Bussy S, Ing AJ, Irving LB, Krimsky WS, Saghaie T, Snell GI, Steinfort DP, Valipour A, Waldstreicher J, Williamson JPOriginally published: American Journal of Respiratory & Critical Care Medicine. 2020 May 14Fiscal year: FY2021Fiscal year of original publication: FY2020Digital Object Identifier: Date added to catalog: 2020-07-09
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 32407638 Available 32407638

Available online from MWHC library: July 1997 - present, Available in print through MWHC library: 1999 - present

CONCLUSIONS: This study provides the first clinical evidence of the feasibility, safety and initial outcomes of Bronchial Rheoplasty in symptomatic chronic bronchitis patients.

MEASUREMENTS AND MAIN RESULTS: Bronchial Rheoplasty was performed in all 30 patients [63% male, mean age 67 (standard deviation 7.4), post-bronchodilator Forced Expiratory Volume in 1 second 65% (21%), COPD Assessment Test score 25.6 (7.1), and St. George's Respiratory Questionnaire score 59.6 (15.3)]. There were no device-related and 4 procedure-related serious adverse events through 6 months, and none thereafter through 12 months. The most frequent non-serious, device and/or procedure related event through 6 months was mild hemoptysis in 47% (14/30) patients. Histologically, mean goblet cell hyperplasia score was statistically significantly reduced (p<0.001). Significant changes from baseline to 6 months in COPD Assessment Test (mean -7.9; median -8.0; p=0.0002) and St. George's Respiratory Questionnaire (mean -14.6; median -7.2; p=0.0002) were observed, with similar observations through 12 months.

METHODS: Pooled analysis of two separate studies enrolling 30 patients undergoing bilateral Bronchial Rheoplasty. Follow-up through 6 months (primary outcome) and 12 months included assessment of adverse events, airway histology and changes in symptoms using the COPD Assessment Test and St. George's Respiratory Questionnaire.

OBJECTIVES: To evaluate the feasibility, safety and initial outcomes of Bronchial Rheoplasty in chronic bronchitis patients.

RATIONALE: Chronic bronchitis is characterized by productive cough with excessive mucus production, resulting in quality of life impairment and increased exacerbation risk. Bronchial Rheoplasty uses an endobronchial catheter to apply non-thermal pulsed electric fields to the airways. Preclinical studies demonstrated epithelial ablation followed by regeneration of normalized epithelium.

English

Powered by Koha